CoChat
Sign Up
Cited by 1,222Pancreatic and Hepatic Oncology ResearchCancer Treatment and PharmacologyPancreatitis Pathology and Treatment

The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Wang-Gillam, Andrea, Li, Chung-Pin, Bodoky, György, Dean, Andrew, Shan, Yan-Shen, Jameson, Gayle, Macarulla, Teresa, Lee, Kyung-Hun, Cunningham, David, Blanc, Jean F, Hubner, Richard A, Chiu, Chang-Fang, Schwartsmann, Gilberto, Siveke, Jens T, Braiteh, Fadi, Moyo, Victor, Belanger, Bruce, Dhindsa, Navreet, Bayever, Eliel, Von Hoff, Daniel D, Chen, Li-Tzong, Adoo, Clarence, Anderson, Thomas, Asselah, Jamil, Azambuja, Alan, Bampton, Carolyn, Barrios, Carlos Henrique, Bekaii-Saab, Tanios, Bohuslav, Melichar, Chang, David, Chen, Jen-Shi, Chen, Yeu-Chin, Choi, Hye Jin, Chung, Ik Joo, Chung, Vincent, Csoszi, Tibor, Cubillo, Antonio, DeMarco, Linda, de Wit, Maike, Dragovich, Tomislav, Edenfield, William, Fein, Luis Enrique, Franke, Fábio, Fuchs, Martin, Gonzales-Cruz, Vega, Gozza, Alberto, Fernando, Rivera Herrero, Iaffaioli, Rosario, Jakesova, Jitka, Kahan, Zsuzsanna, Karimi, Misagh, Kim, Jun Suk, Korbenfeld, Ernesto, Lang, Istvan, Lee, Fa-Chyi, Lee, Kuan-Der, Lipton, Lara, Ma, Wen Wee, Mangel, Laszlo, Mena, Raul, Palmer, Daniel, Pant, Shubham, Park, Joon Oh, Piacentini, Paolo, Pelzer, Uwe, Plazas, Javier Gallego, Prasad, Cooray, Rau, Kun-Ming, Raoul, Jean-Luc, Richards, Donald, Ross, Paul, Schlittler, Luis, Smakal, Martin, Stahalova, Vladimira, Sternberg, Cora, Seufferlein, Thomas, Tebbutt, Niall, Vinholes, Jeferson Jose, Wadlow, Raymond, Wenczl, Milkos, Wong, Mark·2016·The Lancet
DOI 10.1016/s0140-6736(15)00986-1
Open this paper in CoChat — free account

Abstract

Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapies. We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this population.Methods We did a global, phase 3, randomised, open-label trial at 76 sites in 14 countries. Eligible patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy were randomly assigned (1:1) using an interactive web response system at a central location to receive either nanoliposomal irinotecan monotherapy (120 mg/m(2) every 3 weeks, equivalent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid. A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added later (1:1:1), in a protocol amendment. Randomisation was stratified by baseline albumin, Karnofsky performance status, and ethnic origin. Treatment was continued until disease progression or intolerable toxic effects. The primary endpoint was overall survival, assessed in the intention-to-treat population. The primary analysis was planned after 305 events. Safety was assessed in all patients who had received study drug. This trial is registered at ClinicalTrials.gov, number NCT01494506.Findings Between Jan 11, 2012, and Sept 11, 2013, 417 patients were randomly assigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal irinotecan monotherapy (n=151), or fluorouracil and folinic acid (n=149). After 313 events, median overall survival in patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8-8.9) vs 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI 0.49-0.92; p=0.012). Median overall survival did not differ between patients assigned nanoliposomal irinotecan monotherapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4.2 months [3.6-4.9]; 0.99, 0.77-1.28; p=0.94). The grade 3 or 4 adverse events that occurred most frequently in the 117 patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]).Interpretation Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy. This agent represents a new treatment option for this population.Funding Merrimack Pharmaceuticals.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)00986-1

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Cited by

Sorted by citations

See all 1,222

Related

Metadata

Authors
Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., Hubner, R. A., Chiu, C.-F., Schwartsmann, G., Siveke, J. T., Braiteh, F., Moyo, V., Belanger, B., Dhindsa, N., Bayever, E., Von Hoff, D. D., Chen, L.-T., Adoo, C., Anderson, T., Asselah, J., Azambuja, A., Bampton, C., Barrios, C. H., Bekaii-Saab, T., Bohuslav, M., Chang, D., Chen, J.-S., Chen, Y.-C., Choi, H. J., Chung, I. J., Chung, V., Csoszi, T., Cubillo, A., DeMarco, L., de Wit, M., Dragovich, T., Edenfield, W., Fein, L. E., Franke, F., Fuchs, M., Gonzales-Cruz, V., Gozza, A., Fernando, R. H., Iaffaioli, R., Jakesova, J., Kahan, Z., Karimi, M., Kim, J. S., Korbenfeld, E., Lang, I., Lee, F.-C., Lee, K.-D., Lipton, L., Ma, W. W., Mangel, L., Mena, R., Palmer, D., Pant, S., Park, J. O., Piacentini, P., Pelzer, U., Plazas, J. G., Prasad, C., Rau, K.-M., Raoul, J.-L., Richards, D., Ross, P., Schlittler, L., Smakal, M., Stahalova, V., Sternberg, C., Seufferlein, T., Tebbutt, N., Vinholes, J. J., Wadlow, R., Wenczl, M., & Wong, M.
Affiliations
  • Taipei Veterans General Hospital (TW)
  • St John of God Subiaco Hospital (AU)
  • National Cheng Kung University Hospital (TW)
  • Translational Genomics Research Institute (US)
  • Vall d'Hebron Institute of Oncology (ES)
  • Seoul National University Hospital (KR)
  • Royal Marsden Hospital (GB)
  • Hôpital Saint-André (FR)
  • The Christie NHS Foundation Trust (GB)
  • China Medical University Hospital (TW)
  • Hospital de Clínicas de Porto Alegre (BR)
  • TUM Klinikum (DE)
  • Comprehensive Cancer Centers of Nevada (US)
  • Merrimack Pharmaceuticals (United States) (US)
  • Kaohsiung Medical University (TW)
Corresponding author
Chen, Li-Tzong
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2016-02
Volume
387
Issue
10018
Pages
545-557
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(15)00986-1
OpenAlex
W2187917981
Cited by
1,222
References
29
Citations by year
2026: 92 · 2025: 123 · 2024: 122 · 2023: 116 · 2022: 119 · 2021: 156 · 2020: 117 · 2019: 116 · 2018: 99 · 2017: 101 · 2016: 53
FWCI
37.85
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
5-fluorouracil, leucovorin, metastatic pancreatic ductal adenocarcinoma, gemcitabine-refractory disease, combination chemotherapy, overall survival, first-line therapy, NAPOLI-1 trial, albumin, Karnofsky performance status
MeSH terms
Irinotecan, Gemcitabine, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Diarrhea, Fatigue, Female, Fluorouracil, Humans, Liposomes, Male, Middle Aged, Neoplasm Metastasis, Neutropenia, Pancreatic Neoplasms, Vomiting, Treatment Outcome, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review